See every side of every news story
Get Started
SubscribeLogin
Everton
Donald Trump
Ukraine War
Volodymyr Zelenskyy
Viktor Orbán
Hamas
Basketball
Israel-Hamas Conflict
Manchester United
Elon Musk
Premier League
Soccer
Published • loading... • Updated

New Therapy for Chronic Graft-Vs-Host Disease: Axatilimab

Summary by Pharmacy Times
Axatilimab is a colony-stimulating factor-1 receptor–blocking monoclonal antibody indicated after 2 lines of systemic therapy.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Pharmacy TimesPharmacy Times

New Therapy for Chronic Graft-Vs-Host Disease: Axatilimab

Axatilimab is a colony-stimulating factor-1 receptor–blocking monoclonal antibody indicated after 2 lines of systemic therapy.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Pharmacy Times broke the news in on Friday, February 21, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
Search
BlindspotLocal